首页 > 市场调查报告书 > 製药

生物製剂分子标靶治疗学

市场调查报告书

商品编码

2018966

对双特异性抗体药物复合体（BsADCs）的全球临床试验、监管核准、开发平台和市场机会的洞察（2026 年）

Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals, Development Platforms & Market Opportunity Insight 2026

出版日期: 2026年04月01日 | 出版商:

KuicK Research | 英文 240 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

《2026年全球双特异性抗体药物复合体（BsADC）临床试验、监管核准、开发平台和市场机会洞察》报告的亮点和发现：

调查方法
预计首个双特异性抗体药物复合体（BsADC）将于 2028 年获得市场核准。
对超过 150 项 BsADC 临床试验进行了全面分析，按公司、国家、适应症、临床阶段和优先顺序进行分类。
中国在双特异性抗体药物复合体研发方面主导：已完成100多项临床试验。
到2030年，双特异性抗体药物复合体市场的市场机会：超过20亿美元
本公司对双特异性抗体药物复合体(BsADC) 技术平台的分析
竞争格局

双特异性抗体药物复合体的必要性及本报告的意义

双特异性抗体药物复合体）作为抗体药物复合体的演进型药物，代表了结合双特异性抗体优势的下一代抗体疗法。这些分子能够针对两个不同的靶点，从而应对癌症治疗中一些最迫切的挑战。儘管肿瘤微环境的异质性限制了单株抗体和抗体药物复合体在癌症治疗的应用，但BsADCs有望提供更完善的解决方案。

截至2026年4月，全球生物特异性抗体药物偶联物（BsADC）市场尚处于早期阶段，但发展迅速，拥有强大且不断扩展的研发管线，儘管后期研发项目有限。候选药物如isarontamab/brengitecan（Iza-bren，BL-B01D1）已完成临床概念验证（PoC），显示其具有临床成功潜力和未来商业化前景。

本报告整合了科学、临床、技术和商业性观点，全面概述了 BsADC 市场，并为策略决策提供支援。

报告中包含了对临床试验的深入分析。

临床开发是生物活性药物偶联物（BsADC）市场成长的主要驱动力，产品线正迅速扩展，涵盖早期、中期和晚期开发阶段。肿瘤学仍然是主要关注领域，BsADC正在骨髓恶性肿瘤和固态肿瘤中进行评估，尤其是在復发或难治性疾病患者群体中。

后期候选药物的正向临床结果进一步增强了人们对这类疗法的整体信心。例如，Iza-bren 在转移性三阴性乳癌中显示出良好的无恶化生存期和总存活期疗效，并且在 EGFR 突变阳性的非小细胞肺癌中也显示出较高的缓解率。同样，JSKN003 目前正在进行 HER2 阳性乳癌的 III 期临床试验，即使在 HER2 表达水平低或异质性较高的患者中也显示出良好的疗效。

本报告也详细分析了处于各个研发阶段的在研临床试验，探讨了临床试验设计、目标病患群体、剂量和合併用药策略等多个面向。免疫查核点抑制剂与化疗药物联合治疗的日益普及表明，癌症治疗正朝着更综合化的方向发展，而多个后期候选药物的进展也清晰地展现了生物活性药物偶联物（BsADC）研发管线的成熟度。

专注于双特异性抗体药物复合体研发的主要企业

生物活性药物偶联物（BsADC）市场的发展主要得益于传统製药公司和生物技术行业新参与企业的积极参与。四川百利药业、SystImmune等公司目前在先进分子药物（如Iza-bren）的研发方面处于市场领先地位，而Alphamab Oncology则凭藉JSKN003、JSKN033和JSKN027等新型分子药物进一步深化了市场。

新参与企业在推动生物靶向抗体药物偶联物（BsADC）市场发展方面也发挥着重要作用。 Avenzo Therapeutics、Duality Bio、InduPro 等新参与企业凭藉 AVZO-103、DB-1418 和 IDP-001 等新型分子引领市场，这些分子旨在透过双重抗原靶向来应对肿瘤生物学的复杂性。其他新参与企业，例如科伦生物，也凭藉 SKB103 和 SKB571 等分子引领市场。

一份概述双特异性抗体药物复合体片段未来发展方向的报告。

受双特异性抗体药物复合体（BsADC）在临床试验中取得成功、技术进步以及该领域投资的推动，BsADC市场预计在未来几年将迎来显着成长。随着BsADC在临床试验中不断取得进展，它们有望成为一类新型标靶治疗。

联合治疗有望在塑造生物特异性抗体药物偶联物（BsADCs）的未来发展中发挥关键作用。尤其是在肿瘤领域，联合疗法可与免疫疗法和其他标靶治疗合併使用，以改善临床疗效。进一步探索其他疾病领域可望拓宽BsADCs的治疗前景。

总之，在强大的产品平臺、技术进步和策略合作的支持下，双特异性抗体药物复合体有望彻底改变精准医疗和标靶治疗的未来。

Research Methodology
First Bispecific Antibody Drug Conjugate (BsADC) Market Approval Expected By 2028
Comprehensive Insight On More Than 150 BsADC In Clinical Trials By Company, Country, Indication, Phase & Priority Status
China Dominating Bispecific Antibody Drug Conjugate Development: > 100 Clinical Trials
Bispecific Antibody Drug Conjugate Market Opportunity By 2030: > USD 2 Billion
Insight On Bispecific Antibody Drug Conjugates Technologies Platforms By Companies
Competitive Landscape

Need For Bispecific Antibody Drug Conjugates & Why This Report?

Bispecific antibody drug conjugates are emerging as the next generation of antibody based therapies as an evolution of antibody drug conjugates, with the added advantage of bispecific antibodies. These molecules have the ability to target two different targets, enabling them to address some of the most pressing issues in the treatment of cancers. With the limitations of monoclonal antibodies and antibody drug conjugates in the treatment of cancers due to the heterogeneity of the tumor microenvironment, BsADCs are poised to offer more refined solutions to the treatment of cancers.

As of April 2026, the global BsADC market remains in a relatively early but rapidly advancing stage, with limited late stage assets but a strong and expanding pipeline. Candidates such as Izalontamab brengitecan (Iza-bren, BL-B01D1) are demonstrating clinical proof-of-concept, indicating the potential for both clinical success and future commercialization.

This report provides a comprehensive overview of the BsADC market, integrating scientific, clinical, technological, and commercial perspectives to support strategic decision making.

Clinical Trials Insight Included In Report

Clinical development is a major driver of growth in the BsADC market, with a rapidly expanding pipeline across early, mid, and late stages of development. Oncology remains the primary focus, where BsADCs are being evaluated in both hematological malignancies and solid tumors, with particular emphasis on patient populations with relapsed or refractory disease.

The positive clinical results from late-stage candidates are further adding to the overall confidence in this therapeutic class. For example, Iza-bren has shown positive results in terms of progression-free survival and overall survival in metastatic triple-negative breast cancer, and response rates in EGFR mutant non-small cell lung cancer. Similarly, JSKN003 is currently in Phase III trials for HER2-positive breast cancer and has also shown positive results even in patients with low or heterogeneous HER2 expression levels.

The report also includes a detailed analysis of clinical trials currently underway, including those in all phases of development, and discusses various aspects such as clinical trial design, patient population, dose and combination strategies, and so on. The increased focus on combination therapies with immune checkpoint inhibitors and chemotherapy agents also indicates a shift toward a more combined approach in cancer therapies, and the progress of several candidates in late-stage development also speaks volumes for the maturity of the BsADC pipeline.

Major Companies Active In R&D Of Bispecific Antibody Drug Conjugates

The BsADC market has been driven by the active engagement of both traditional pharmaceutical companies and new entrants in the biotechnology industry. Sichuan Baili Pharmaceutical, SystImmune, and other companies are currently the market leaders in the development of advanced molecules, including Iza-bren, while Alphamab Oncology continues to enhance the depth of the market with new molecules, including JSKN003, JSKN033, and JSKN027.

New entrants are also playing an instrumental role in propelling the BsADC market forward. Avenzo Therapeutics, Duality Bio, InduPro, and other new entrants are driving the market with new molecules, including AVZO-103, DB-1418, and IDP-001, which are designed to address the complexities of tumor biology through dual-antigen targets. Other new entrants, including Kelun-Biotech, are driving the market with molecules, including SKB103 and SKB571.

Report Indicating Future Direction Of Bispecific Antibody Drug Conjugate Segment

The bispecific antibody drug conjugate market is expected to grow considerably in the coming years, driven by the success of bispecific antibody drug conjugates in clinical trials, technology advancements, and investments in the field. As bispecific antibody drug conjugates continue to progress in clinical trials, they are expected to emerge as a new class of targeted therapies.

Combination therapy is expected to play a critical role in shaping the future of BsADCs, particularly in oncology, where they may be used alongside immunotherapies and other targeted agents to improve clinical outcomes. Expanding research into additional disease areas may further broaden the therapeutic potential of BsADCs.

In conclusion, bispecific antibody drug conjugates, driven by a strong product pipeline, technology advancements, and strategic partnerships, are expected to revolutionize the future of precision medicine and targeted therapies.

1. Conception & Ongoing Development Of Bispecific Antibody Drug Conjugates

1.1 Overview
1.2 Comparison With Other Immunotherapies

2. Need For Bispecific Antibody Drug Conjugates

3. Bispecific Antibody Drug Conjugates - Design & Mechanism Of Action

3.1 General Structure & Design
3.2 Mechanism Of Action

4. Global Bispecific Antibody Drug Conjugate Market Insight

4.1 Current Market Scenario
4.2 Future Market Opportunity

5. Bispecific Antibody Drug Conjugates Market Analysis by Region

5.1 China
5.2 US
5.3 Europe
5.4 South Korea

6. Bispecific Antibody Drug Conjugates - Application & Development By Indication

6.1 Breast Cancer
6.2 Gastrointestinal Cancer
6.3 Lung Cancer
6.4 Urologic Cancers
6.5 Gynecologic Cancers

7. Global Bispecific Antibody Drug Conjugates Clinical Trials Overview

7.1 By Phase
7.2 By Company
7.3 By Country
7.4 By Indication

8. Bispecific Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase I/II
8.5 Phase II
8.6 Phase III
8.7 Preregistration

9. Bispecific Antibody Drug Conjugates Technologies Platforms By Companies

10. Competitive Landscape

10.1 Almac Discovery
10.2 Alphamab Oncology
10.3 Amgen
10.4 AskGene Pharma
10.5 AstraZeneca
10.6 Beijing Biocytogen
10.7 BiVictriX Therapeutics
10.8 Bright Biologics
10.9 Corellia AI
10.10 CStone Pharmaceuticals
10.11 Debiopharm
10.12 Doma Bio
10.13 DualityBio
10.14 Enduring Biotech
10.15 Genmab
10.16 InduPro
10.17 Innovent Biologics
10.18 Kanaph Therapeutics
10.19 ProEn Therapeutics
10.20 SystImmune

简介目录图表

List of Figures

Figure 1-1: Future Directions In BsADC Development
Figure 1-2: Limitations Of Convectional Immunotherapies Addressable By BsADCs
Figure 3-1: Bispecific Antibody Drug Conjugate - General Structure
Figure 3-2: Bispecific Antibody Drug Conjugate - General Mechanism of Action
Figure 4-1: Bispecific Antibody Drug Conjugate Market Forecast - Projections for First 12 & 24 Months Post Approval Of First Drug (US$ Million)
Figure 4-2: Key Future Opportunities
Figure 6-1: BL-B01D1-306 Phase III (NCT06343948) Study - Initiation & Estimated Completion Year
Figure 6-2: BL-B01D1-307 Phase III (NCT06382142) Study - Initiation & Estimated Completion Year
Figure 6-3: BL-B01D1-204-04 Phase II (NCT06471205) Study - Initiation & Estimated Completion Year
Figure 6-4: BL-B01D1-LUNG-101 Phase I (NCT05983432) Study - Initiation & Estimated Completion Year
Figure 6-5: BL-B01D1-104 Phase I (NCT05470348) Study - Initiation & Estimated Completion Year
Figure 6-6: KM501-1001 Phase I (NCT05804864) Study - Initiation & Estimated Completion Year
Figure 6-7: JSKN016-202 Phase I/II (NCT06942234) Study - Initiation & Estimated Completion Year
Figure 6-8: BL-B01D1-SI-B003-201-05 Phase II (NCT06008054) Study - Initiation & Estimated Completion Year
Figure 6-9: BL-B01D1-103 Phase I (NCT05262491) Study - Initiation & Estimated Completion Year
Figure 6-10: BL-B01D1-302 Phase III (NCT06382129) Study - Initiation & Estimated Completion Year
Figure 6-11: BL-B01D1-301 Phase III (NCT06382116) Study - Initiation & Estimated Completion Year
Figure 6-12: BL-B01D1-304 Phase III (NCT06500026) Study - Initiation & Estimated Completion Year
Figure 6-13: IZABRIGHT-Lung01 Phase II/III (NCT07100080) Study - Initiation & Estimated Completion Year
Figure 6-14: AVENTINE-1 Phase I/II (NCT07038343) Study - Initiation & Estimated Completion Year
Figure 6-15: DM001001 Phase II (NCT06475937) Study - Estimated Initiation & Estimated Completion Year
Figure 6-16: EGRET Phase I (NCT05647122) Study - Estimated Initiation & Estimated Completion Year
Figure 6-17: BL-B01D1-201 Phase II (NCT05785039) Study - Initiation & Estimated Completion Year
Figure 6-18: BL-B01D1-102 Phase I (NCT05393427) Study - Initiation & Estimated Completion Year
Figure 6-19: IZABRIGHT-Bladder01 Phase II/III (NCT07106762) Study - Initiation & Estimated Completion Year
Figure 6-20: AVZO-103-1001 Phase I/II (NCT07193511) Study - Initiation & Estimated Completion Year
Figure 6-21: BL-B01D1-SI-B003-201-08 Phase II (NCT05990803) Study - Initiation & Estimated Completion Year
Figure 6-22: BL-B01D1-202 Phase Ib/II (NCT05803018) Study - Initiation & Estimated Completion Year
Figure 6-23: IMGN151-1001 Phase I (NCT05527184) Study - Initiation & Estimated Completion Year
Figure 6-24: JSKN003-102 Phase I/II (NCT05744427) Study - Initiation & Estimated Completion Year
Figure 7-1: Global - Bispecific Antibody Drug Conjugates Clinical Pipeline By Phase (Numbers), 2026
Figure 7-2: Global - Bispecific Antibody Drug Conjugates Clinical Pipeline By Company (Numbers), 2026
Figure 7-3: Global - Bispecific Antibody Drug Conjugates Clinical Pipeline By Country (Numbers), 2026
Figure 7-4: Global - Bispecific Antibody Drug Conjugates Clinical Pipeline By Indication (Numbers), 2026
Figure 9-1: ArbeleBio - Unnamed ADC Platform
Figure 9-2: BiVictriX - Bi-Cygni Therapeutics
Figure 9-3: Duality Biologics - DITAC Platform
Figure 9-4: Duality Biologics - DITAC Platform
Figure 9-5: LigaChem Biosciences - ConjuALL
Figure 9-6: LigaChem Biosciences - Conjugation Method
Figure 9-7: LigaChem Biosciences - B-Glucuronide Linker
Figure 9-8: LigaChem Biosciences - B-Glucuronide Linker
Figure 9-9: ProEn Therapeutics - ArtBody(TM) ADC technology
Figure 9-10: Synaffix - Proprietary Technologies

List of Tables

Table 1-1: BsADC vs. Conventional ADC
Table 1-2: Bispecific Antibody Formats
Table 6-1: Izalontamab brengitecan - Ongoing Lung Cancer Trials

02-2729-4219

+886-2-2729-4219

License/价格

对双特异性抗体药物复合体（BsADCs）的全球临床试验、监管核准、开发平台和市场机会的洞察（2026 年）

Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals, Development Platforms & Market Opportunity Insight 2026

目录

第一章：双特异性抗体药物复合体的构思与持续发展

第二章：双特异性抗体药物复合体的必要性

第三章：双特异性抗体药物复合体－设计与作用机制

第四章：全球双特异性抗体药物复合体市场概述

第五章：双特异性抗体药物复合体市场分析（按地区划分）

第六章：双特异性抗体药物复合体－特定适应症的应用与开发

第七章双特异性抗体药物复合体临床试验概述

第八章：双特异性抗体药物复合体临床试验概况（按公司、国家、适应症和阶段划分）

第九章：各公司的双特异性抗体药物复合体技术平台

第十章竞争格局

Table of Contents